208 related articles for article (PubMed ID: 35550030)
21. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
22. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract][Full Text] [Related]
23. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression.
Grabowska MM; Elliott AD; DeGraff DJ; Anderson PD; Anumanthan G; Yamashita H; Sun Q; Friedman DB; Hachey DL; Yu X; Sheehan JH; Ahn JM; Raj GV; Piston DW; Gronostajski RM; Matusik RJ
Mol Endocrinol; 2014 Jun; 28(6):949-64. PubMed ID: 24801505
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
25. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
26. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
27. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.
Song B; Park SH; Zhao JC; Fong KW; Li S; Lee Y; Yang YA; Sridhar S; Lu X; Abdulkadir SA; Vessella RL; Morrissey C; Kuzel TM; Catalona W; Yang X; Yu J
J Clin Invest; 2019 Feb; 129(2):569-582. PubMed ID: 30511964
[TBL] [Abstract][Full Text] [Related]
28. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
29. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
30. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
31. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.
Linder S; Hoogstraat M; Stelloo S; Eickhoff N; Schuurman K; de Barros H; Alkemade M; Bekers EM; Severson TM; Sanders J; Huang CF; Morova T; Altintas UB; Hoekman L; Kim Y; Baca SC; Sjöström M; Zaalberg A; Hintzen DC; de Jong J; Kluin RJC; de Rink I; Giambartolomei C; Seo JH; Pasaniuc B; Altelaar M; Medema RH; Feng FY; Zoubeidi A; Freedman ML; Wessels LFA; Butler LM; Lack NA; van der Poel H; Bergman AM; Zwart W
Cancer Discov; 2022 Sep; 12(9):2074-2097. PubMed ID: 35754340
[TBL] [Abstract][Full Text] [Related]
32. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
Kregel S; Szmulewitz RZ; Vander Griend DJ
Prostate; 2014 Nov; 74(15):1530-43. PubMed ID: 25175748
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
[TBL] [Abstract][Full Text] [Related]
34. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
36. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
37. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
39. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
40. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
